Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Vulnerability of the locus coeruleus-entorhinal cortex white matter tract in autosomal dominant Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Clinical and biological relevance of objectively-defined subtle cognitive decline in Alzheimer's disease: a narrative review of neuroimaging, biomarker, and clinical progression studies.

The journal of prevention of Alzheimer's disease·2026
Same author

Sex differences in diffusion-weighted imaging outcomes in autosomal dominant Alzheimer's disease.

Brain communications·2026
Same author

Web-based LAS-FNAME and blood biomarkers in autosomal dominant Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Long-term forgetting, sleep, and tau in autosomal-dominant Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Contribution of local amyloid-β and tau burden to hypometabolism in autosomal-dominant Alzheimer's disease.

Brain communications·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Vincent Malotaux1,2, David Fernando Aguillón Niño3, Isabela Gonzalez1

  • 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

通过改变大脑结构,APOE3-Christchurch 变异可能会预防阿尔茨海默病. 异合体载体在额头和顶部区域的皮质厚度增加,可能增强认知储备并延迟疾病发作.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经成像是一种神经成像.
  • 遗传学 遗传学 是一个
  • 阿尔茨海默氏症疾病研究研究

背景情况:

  • APOE3-Christchurch (APOE3Ch) 变种与对阿尔茨海默病 (AD) 的保护有关.
  • 了解AD抗性的机制对于开发有效的干预措施至关重要.
  • 结构神经成像可以揭示与AD抗性相关的早期大脑变化.

研究的目的:

  • 与非载体相比,研究中年异合体APOE3Ch载体中早期结构性大脑差异.
  • 分析皮层厚度 (CT) 模式与AD风险和保护因素相关.

主要方法:

  • 结构性MRI扫描来自52名非痴呆症患者 (15名APOE3Ch携带者,37名非携带者).
  • 基于voxel的形态测量和FreeSurfer分析被用来评估68个感兴趣区域的皮质厚度.
  • 收集了临床措施,包括迷你心理状态考试 (MMSE) 和功能评估分期工具 (FAST) 的分数.

主要成果:

  • 携带APOE3Ch的携带者表现出前额和顶部区域CT的增加,以及尾部和部区域CT的减少.
  • 运营商和非运营商之间没有观察到MMSE或FAST得分的显著差异.
  • 与AD相关的感兴趣元区域的皮层厚度在两组之间是可比的.

结论:

  • 异合体的APOE3Ch载体表现出明显的早期皮质厚度模式,在前侧-双侧区域的厚度更大.
  • 这些前侧-双侧变化可能有助于增强认知储备,可能延迟AD发病.
  • 在APOE3Ch载体中的结构性大脑差异可能是他们观察到的对阿尔茨海默病的抵抗力的基础.